In December 2024, the pharma industry reported 82 deals worth $5.2 billion, compared to the last 12-month (December 2023 to November 2024) average of 100 deals worth $16.8 billion.
Goldman Sachs Asset Management, to acquire a majority stake in Synthon International Holdings BV, a company engaged in developing, manufacturing, and out-licensing complex generic medicines, for a consideration of approximately $2.1 billion; AlpInvest Partners B.V. and Sixth Street Specialty Lending, investing $945.6 million in Essential Holdings, a manufacturer and supplier of specialty pharmaceutical products; and Intas Pharmaceuticals, to acquire UDENYCA Franchise, from Coherus BioSciences, for a consideration of $558.4 million.
These were the three major deals that contributed 70 per cent of the total deal value during December 2024.
| Deal Date | Acquirer (s) | Target | Deal Value ($M) |
| 16-Dec-24 | Goldman Sachs Asset Management LP (US) | Synthon International Holdings BV (Netherlands) | 2,100.2 |
| 12-Dec-24 | AlpInvest Partners B.V. (Netherlands); Sixth Street Specialty Lending Inc (US) | Essential Holdings Ltd (United Kingdom) | 945.6 |
| 02-Dec-24 | Intas Pharmaceuticals Ltd (India) | UDENYCA Franchise (US) | 558.4 |
| 13-Dec-24 | GSK plc (United Kingdom) | Relation Therapeutics Inc (US) | 308.0 |
| 13-Dec-24 | AbbVie Inc (US) | Nimble Therapeutics Inc (US) | 200.0 |
Data provided by GlobalData